Thursday, 16 May 2019
Key points:
A clinical-stage regenerative medicine company
Portfolio of innovative cellular therapies
These target significant unmet medical needs with a licence-driven strategy
Focus on osteoarthritis and other musculoskeletal disorders
Focus on neuropathic pain and dermatology
Lead drug in knee osteoarthritis (US$5 billion addressable market)
